Marik Paul E
Division of Pulmonary and Critical Care Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Expert Opin Pharmacother. 2006 Feb;7(3):297-305. doi: 10.1517/14656566.7.3.297.
Renal, liver, heart and lung transplantation are now considered to be the standard therapeutic interventions in patients with end-stage organ failure. Infectious complications following transplantation are relatively common due to the transplant recipients overall immunosuppressed status. The incidence of invasive mycoses following solid organ transplant ranges from 5 to 42% depending on the organ transplanted. These mycoses are associated with high overall mortality rates. Candida and Aspergillus spp. produce most of these infections. This article will review the risk factors, clinical presentation and treatment of invasive fungal infections in solid organ transplant patients, and evaluate the role of prophylactic therapy in this group of patients.
肾、肝、心和肺移植目前被认为是终末期器官衰竭患者的标准治疗干预措施。由于移植受者总体处于免疫抑制状态，移植后感染并发症相对常见。实体器官移植后侵袭性真菌病的发生率在5%至42%之间，具体取决于所移植的器官。这些真菌病与总体高死亡率相关。念珠菌和曲霉菌属导致了这些感染中的大部分。本文将综述实体器官移植患者侵袭性真菌感染的危险因素、临床表现和治疗，并评估预防性治疗在这类患者中的作用。
